


## Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression (Khanna D et al)

### Supplemental Material

#### Supplementary Figure Prevalence of combinations of risk factors for rapid FVC decline.



The figure is based on subjects in the SENSICIS trial for whom at least one of the risk factors for rapid FVC decline (<18 months since onset of first non-Raynaud symptom ["Duration <18 months"], mRSS 15-40, elevated inflammatory markers ["High CRP/PLT"], or diffuse cutaneous SSc ["dcSSc"]) was present at baseline (N=421). It shows all intersections of sets and their sizes for the risk factors (vertical bars) and marginal sums (horizontal bars) in a matrix layout. For each set that is part of a given intersection, a black circle is placed in the corresponding matrix cell. Each subject is considered in only one column. To obtain the size of the total set or the size of a bivariate or trivariate intersection irrespective of the presence of other variables, the corresponding columns can be added up. The data are provided in a tabular form, stratified by treatment arm, in the Supplementary Table.

Abbreviations: dcSSc, diffuse cutaneous SSc; mRSS, modified Rodnan skin score.

**Supplementary Table** Prevalence of combinations of risk factors for rapid FVC decline.

	<b>Nintedanib</b>	<b>Placebo</b>	<b>Total</b>
mRSS 15-40 and dcSSc	42	39	81
dcSSc	37	36	73
High CRP/PLT	32	33	65
mRSS 15-40 and high CRP/PLT and dcSSc	38	26	64
High CRP/PLT and dcSSc	20	32	52
Duration <18 months	17	17	34
Duration <18 months and high CRP/PLT	6	7	13
Duration <18 months and mRSS 15-40 and dcSSc	6	3	9
Duration <18 months and mRSS 15-40 and high CRP/PLT and dcSSc	5	3	8
Duration <18 months and dcSSc	3	4	7
Duration <18 months and high CRP/PLT and dcSSc	2	3	5
mRSS 15-40	3	2	5
Duration <18 months and mRSS 15-40	1	1	2
mRSS 15-40 and high CRP/PLT	1	1	2
Duration <18 months and mRSS 15-40 and high CRP/PLT	0	1	1

Subjects in the SENSICIS trial for whom at least one of the risk factors for rapid FVC decline (<18 months since onset of first non-Raynaud symptom ["Duration <18 months"], mRSS 15-40, elevated inflammatory markers ["High CRP/PLT"], or diffuse cutaneous SSs ["dcSSc"]) was present at baseline (N=421).  
Abbreviations: dcSSc, diffuse cutaneous SSs; mRSS, modified Rodnan skin score.